NCT03840772View on ClinicalTrials.gov

Eribulin in Advanced Solitary Fibrous Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Solitary Fibrous Tumor
Interventions
DRUG

Eribulin

Treatment with eribulin

Trial Locations (3)

20133

Fondazione IRCCS INT Milano, Milan

90127

Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo

00128

Policlinico Universitario Campus Biomedico, Roma

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Italian Sarcoma Group

NETWORK

NCT03840772 - Eribulin in Advanced Solitary Fibrous Tumor | Biotech Hunter | Biotech Hunter